Olema Oncology to Present New Palazestrant Clinical Data in Combination with CDK4/6 Inhibitors at the 2023 San Antonio Breast Cancer Symposium (SABCS)
November 28 2023 - 5:10PM
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq:
OLMA), a clinical-stage biopharmaceutical company focused on the
discovery, development and commercialization of targeted therapies
for women’s cancers, today announced that it will be presenting new
Phase 1b/2 clinical data of palazestrant (OP-1250) in combination
with CDK4/6 inhibitor ribociclib, a Poster Spotlight Session on
Phase 2 clinical data of palazestrant in combination with
palbociclib, and a trial-in-progress poster for the OPERA-01
monotherapy Phase 3 pivotal trial at the upcoming San Antonio
Breast Cancer Symposium (SABCS) being held December 5-9, 2023, at
the Henry B. Gonzalez Convention Center in San Antonio,
Texas.
Details of the SABCS 2023 poster presentations
are:
Title: |
A
Phase 1b/2 study of palazestrant (OP-1250) in combination with
ribociclib in patients with estrogen receptor-positive, human
epidermal growth factor receptor 2-negative, advanced and/or
metastatic breast cancer. |
Poster ID: |
PO4-04-12 |
Session
Title: |
Poster Session 4 |
Date &
Time: |
Thursday, December 7, 2023, 5:00
– 7:00 p.m. CT |
Location: |
Halls 2-3 |
Title: |
A
Phase 1b/2 study of palazestrant (OP-1250), an oral complete
estrogen receptor antagonist (CERAN) and selective ER degrader
(SERD), with palbociclib in ER-positive, HER2-negative, advanced or
metastatic breast cancer patients. |
Presenter: |
Arlene Chan, FRACP, MMed, Breast
Cancer Research Centre-WA, Curtin University, Breast Clinical
Trials Unit, Hollywood Private Hospital, Nedlands, Australia |
Poster ID: |
PS15-04 |
Session
Title: |
Novel Nuclear Receptor Targeting
Therapies |
Date &
Time: |
Thursday, December 7, 2023, 5:30
– 6:30 p.m. CT |
Location: |
Stars at Night Ballroom 1-2 |
Title: |
OPERA-01: A randomized, open-label, phase 3, study of palazestrant
(OP-1250) vs standard-of-care treatment for ER+, HER2- advanced or
metastatic breast cancer after endocrine and CDK4/6 inhibitor
therapy. |
Poster ID: |
PO3-18-09 |
Session
Title: |
Poster Session 3 |
Date &
Time: |
Thursday, December 7, 2023, 12:00
– 2:00 p.m. CT |
Location: |
Halls 2-3 |
A copy of the presentations will be made available on Olema’s
website under the Science section when it is presented at the
symposium. Abstracts for the posters can be found on the SABCS 2023
website here.
Company Investor Webcast and Conference
Call
Olema will host a webcast and conference call for analysts and
investors to review data presented at SABCS 2023 as well as other
ongoing studies on Friday, December 8, 2023, at 8:00 a.m. ET (7:00
a.m. CT). Please register for the webcast by visiting the Investors
& Media section of Olema’s website at olema.com.
About Olema OncologyOlema Oncology is a
clinical-stage biopharmaceutical company focused on the discovery,
development and commercialization of targeted therapies for women’s
cancers. Olema’s lead product candidate, palazestrant (OP-1250), is
a proprietary, orally-available small molecule with dual activity
as both a complete estrogen receptor (ER) antagonist (CERAN) and a
selective ER degrader (SERD). It is currently being evaluated both
as a single agent in an ongoing Phase 3 clinical trial, and in
combination with CDK4/6 inhibitors (palbociclib and ribociclib) and
a PI3Ka inhibitor (alpelisib), in patients with recurrent, locally
advanced or metastatic ER-positive (ER+), human epidermal growth
factor receptor 2-negative (HER2-) breast cancer. Palazestrant has
been granted FDA Fast Track designation for the treatment of
ER+/HER2- metastatic breast cancer that has progressed following
one or more lines of endocrine therapy with at least one line given
in combination with a CDK4/6 inhibitor. Olema is headquartered in
San Francisco and has operations in Cambridge, Massachusetts. For
more information, please visit us at www.olema.com, or follow us on
Twitter and LinkedIn.
Contact:Geoffrey Mogilner, Vice President, Investor Relations
and Communicationsir@olema.com
Olema Pharmaceuticals (NASDAQ:OLMA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Olema Pharmaceuticals (NASDAQ:OLMA)
Historical Stock Chart
From Jul 2023 to Jul 2024